# Supplementary Table 2: List of 60 studies using a formal EKE process that were reviewed and scored in Part 2

1. Asseburg C, Frank M, Kohne CH, et al. Cost-effectiveness of targeted therapy with cetuximab in patients with K-ras wild-type colorectal cancer presenting with initially unresectable metastases limited to the liver in a German setting. Clin Ther. 2011;33:482-97.
2. Chen W, Jiang Z, Shao Z, Sun Q, Shen K. An economic evaluation of adjuvant trastuzumab therapy in HER2-positive early breast cancer. Value in health. 2009;12:Suppl 3**,**S82-4.
3. Gani R, Griffin J, Kelly S, Rutten-Van Molken M. Economic analyses comparing tiotropium with ipratropium or salmeterol in UK patients with COPD. Primary Care Respiratory Journal. 2010;19:68-74.
4. Faber A, van Agthoven M, Kalverdijk LJ, et al. Long-acting methylphenidate-OROS in youths with attention-deficit hyperactivity disorder suboptimally controlled with immediate-release methylphenidate: a study of cost effectiveness in The Netherlands. CNS drugs. 2008;22:157-70.
5. Damen J, Thuresson PO, Heeg B, Lothgren M. A pharmacoeconomic analysis of compliance gains on antipsychotic medications. Applied Health Economics and Health Policy. 2008;6:189-97.
6. Punekar YS, Hawkins N. Cost-effectiveness of infliximab for the treatment of acute exacerbations of ulcerative colitis*.* Eur J Health Econ*.* 2010;11:67-76.
7. Tavakoli M, Pumford N, Woodward M, et al. An economic evaluation of a perindopril-based blood pressure lowering regimen for patients who have suffered a cerebrovascular event. Eur J Health Econ. 2009;10:111-9.
8. Rotstein C, Cragin L, Laverdiere M, et al. Economic evaluation of voriconazole for the treatment of candidemia in Canadian adults. Can J Infect Dis MedMicrobiol. 2008;19**:**219-26.
9. Brown B, Diamantopoulos A, Bernier J, et al. An economic evaluation of cetuximab combined with radiotherapy for patients with locally advanced head and neck cancer in Belgium, France, Italy, Switzerland, and the United Kingdom. Value in health. 2008;11**,**791-9.
10. Al-Badriyeh D, Liew D, Stewart K, Kong DC. Cost-effectiveness evaluation of voriconazole versus liposomal amphotericin B as empirical therapy for febrile neutropenia in Australia. J Antimicrob Chemother. 2009;63:197-208.
11. Prosser LA, Bridges CB, Uyeki TM, et al. Health benefits, risks, and cost-effectiveness of influenza vaccination of children. Emerg Infect Dis. 2006;12:1548-58.
12. Schurmann D, Sorensen SV, de Cock E, Duttagupta S, Resch A. Cost-effectiveness of linezolid versus vancomycin for hospitalised patients with complicated skin and soft-tissue infections in Germany. Eur J Health Econ. 2009;10:65-79.
13. Al MJ, Maniadakis N, Grijseels EWM, Janssen M. Costs and effects of various analgesic treatments for patients with rheumatoid arthritis and osteoarthritis in The Netherlands. Value in health. 2008;11:589-599.
14. Benedict A, Arellano J, de Cock E, Baird J. Economic evaluation of duloxetine versus serotonin selective reuptake inhibitors and venlafaxine XR in treating major depressive disorder in Scotland. J Affect Disord. 2010;120:94-104.
15. Xu X, Ivy JS, Patel DA, et al. Pelvic Floor Consequences of Cesarean Delivery on Maternal Request in Women with a Single Birth: A Cost-effectiveness Analysis. J Womens Health. 2010;19:147-160.
16. Risebrough NA, Verma S, Trudeau M, Mittmann N. Cost-effectiveness of switching to exemestane versus continued tamoxifen as adjuvant therapy for postmenopausal women with primary breast cancer. Cancer. 2007;110:499-508.
17. Veenstra DL, Sullivan SD, Lai MY, et al. HBeAg-negative chronic hepatitis B: cost-effectiveness of peginterferon alfa-2a compared to lamivudine in Taiwan. Value in health. 2008;11**:**131-8.
18. Talbird SE, Taylor TN, Knoll S, Frostad CR, Garcia Marti S. Outcomes and costs associated with PHiD-CV, a new protein D conjugate pneumococcal vaccine, in four countries. Vaccine. 2010; 28 Suppl 6**,** G23-9.
19. Dakin H, Nuijten M, Liedgens H, Nautrup BP. Cost-effectiveness of a lidocaine 5% medicated plaster relative to gabapentin for postherpetic neuralgia in the United Kingdom. Clin Ther. 2007;29:1491-507.
20. Riddle MS, Tribble DR, Cachafiero SP, Putnam SD, Hooper TI. Development of a travelers' diarrhea vaccine for the military: how much is an ounce of prevention really worth? Vaccine. 2008;26**,**2490-502.
21. Giglio ND, Cane AD, Micone P, Gentile A. Cost-effectiveness of the CRM-based 7-valent pneumococcal conjugated vaccine (PCV7) in Argentina. Vaccine. 2010;28**:**2302-10.
22. Jurgensen JS, Arns W, Hass B. Cost-effectiveness of immunosuppressive regimens in renal transplant recipients in Germany: a model approach. Eur J Health Econ. 2010;11:15-25.
23. Cipriano LE, Rupar CA, Zaric GS. The cost-effectiveness of expanding newborn screening for up to 21 inherited metabolic disorders using tandem mass spectrometry: results from a decision-analytic model. Value in health. 2007;10:83-97.
24. Sado M, Knapp M, Yamauchi K, et al. Cost-effectiveness of combination therapy versus antidepressant therapy for management of depression in Japan. Aust N Z J Psychiatry. 2009;43:539-47.
25. Casado A, Secades JJ, Ibarz R, Herdman M, Brosa M. Cost-effectiveness of citicoline versus conventional treatment in acute ischemic stroke. Expert Rev. Pharmacoeconomics Outcomes Res. 2008;8**:**151-7.
26. de Cock E, Krueger WA, Sorensen S, et al. Cost-effectiveness of linezolid vs vancomycin in suspected methicillin-resistant Staphylococcus aureus nosocomial pneumonia in Germany. Infection. 2009;37:123-32.
27. Andersson KL, Salomon JA, Goldie SJ, Chung RT. Cost effectiveness of alternative surveillance strategies for hepatocellular carcinoma in patients with cirrhosis. Baillieres Clin Gastroenterol Haematol. 2008;6**,**1418-24.
28. Rogers G, Garside R, Mealing S, et al. Carmustine implants for the treatment of newly diagnosed high-grade gliomas: a cost-utility analysis. Pharmacoeconomics. 2008;26:33-44.
29. Xie F, Despiegel N, Danchenko N, Hansen K. Cost effectiveness analysis of escitalopram compared to venlafaxine and fluvoxamine in treatment of major depressive disorder. Int J Psychiatry Clin Prac. 2009;13:59-69.
30. Clark TJ, Barton PM, Coomarasamy A, Gupta JK, Khan KS. Investigating postmenopausal bleeding for endometrial cancer: cost-effectiveness of initial diagnostic strategies. Br J Obstet Gynaecol. 2006;113:502-10.
31. Goodacre Sm, Stevenson M, Wailoo A, et al. How should we diagnose suspected deep-vein thrombosis? QJM-Int J Med. 2006;99:377-88.
32. Jansen JP, Pellissier J, Choy EH, et al. Economic evaluation of etoricoxib versus non-selective NSAIDs in the treatment of ankylosing spondylitis in the UK. Curr Med Res Opin. 2007;23:3069-78.
33. Caekelbergh K, Annemans L, Lambert J, Roelandts R. Economic evaluation of methyl aminolaevulinate-based photodynamic therapy in the management of actinic keratosis and basal cell carcinoma. Br J Dermatol. 2006;155**,**784-90.
34. Locker GY, Mansel R, Cella D, et al. Cost-effectiveness analysis of anastrozole versus tamoxifen as primary adjuvant therapy for postmenopausal women with early breast cancer: a US healthcare system perspective. The 5-year completed treatment analysis of the ATAC ('Arimidex', Tamoxifen Alone or in Combination) trial. Breast Cancer Res Treat. 2007;106**,** 229-38.
35. Fonseca MC, Araujo GT, Araujo DV. Cost effectiveness of peginterferon alfa-2B combined with ribavirin for the treatment of chronic hepatitis C in Brazil. Braz J Infect Dis. 2009;13**,**191-9.
36. Martín-Jiménez M, Rodríguez-Lescure A, Ruiz-Borrego M, Seguí-Palmer MA, Brosa-Riestra M. Cost-effectiveness analysis of docetaxel (Taxotere®) vs. 5-fluorouracil in combined therapy in the initial phases of breast cancer. Clin Transl Oncol. 2009;11:41-47.
37. Hoerger TJ, Wittenborn JS, Segel JE, et al. A health policy model of CKD: 2. The cost-effectiveness of microalbuminuria screening. Am J Kidney Dis. 2010;55**:**463-73.
38. Buti M, Casado MA, Calleja JL, et al. Cost-effectiveness analysis of lamivudine and adefovir dipivoxil in the treatment of patients with HBeAg-negative chronic hepatitis B. Aliment Pharmacol Ther. 2006;23**,**409-19.
39. Somerville M, Garside R, Pitt M, Stein K. Surveillance of Barrett's oesophagus: is it worthwhile? Eur J Cancer. 2008;44:588-99.
40. Smith KJ, Zimmerman RK, Lin CJ, et al. Alternative strategies for adult pneumococcal polysaccharide vaccination: a cost-effectiveness analysis. Vaccine. 2008;26:1420-31.
41. Lenox-Smith A, Greenstreet L, Burslem K, Knight C. Cost effectiveness of venlafaxine compared with generic fluoxetine or generic amitriptyline in major depressive disorder in the UK. Clin Drug Investig. 2009;29:173-84.
42. Ritchie M, Liedgens H Nuijten M. Cost effectiveness of a lidocaine 5% medicated plaster compared with pregabalin for the treatment of postherpetic neuralgia in the UK: a Markov model analysis. Clin Drug Investig. 2010;30,71-87.
43. Stevenson MD, Scope A, Sutcliffe PA. The cost-effectiveness of group cognitive behavioral therapy compared with routine primary care for women with postnatal depression in the UK. Value in health. 2010;13**:**580-4.
44. Carroll AE, Downs SM. Comprehensive cost-utility analysis of newborn screening strategies. Pediatric. 2006;117**:**S287-95.
45. Lin WA, Tarn YH, Tang SL. Cost-utility analysis of different peg-interferon alpha-2b plus ribavirin treatment strategies as initial therapy for naive Chinese patients with chronic hepatitis C. Aliment Pharmacol Ther. 2006;24:1483-93.
46. Smith KJ, Zimmerman RK, Nowalk MP, Roberts MS. Age, revaccination, and tolerance effects on pneumococcal vaccination strategies in the elderly: a cost-effectiveness analysis. Vaccine. 2009;27:3159-64.
47. Andersen B, Gundgaard J, Kretzschmar M, et al. Prediction of costs, effectiveness, and disease control of a population-based program using home sampling for diagnosis of urogenital Chlamydia trachomatis Infections. Sex Transm Dis. 2006;33**:**407-15.
48. Thompson B, Thompson LA, Chan NL, Hislop TG, Taylor VM. Cost effectiveness of cervical cancer screening among Chinese women in north America. APJCP. 2007;8**:**287-293.
49. Yang L, Li M, Tao LB, et al. Cost-effectiveness of long-acting risperidone injection versus alternative atypical antipsychotic agents in patients with schizophrenia in China. Value in health. 2009;12:Suppl 3,S66-9.
50. Mckenna C, Mcdaid C, Suekarran S, et al. Enhanced external counterpulsation for the treatment of stable angina and heart failure: a systematic review and economic analysis. Health technology assessment. 2009;13**,** iii-iv, ix-xi, 1-90.
51. Furiak NM, Ascher-Svanum H, Klein RW, et al. Cost-effectiveness of olanzapine long-acting injection in the treatment of patients with schizophrenia in the United States: a micro-simulation economic decision model. Curr Med Res Opin**.** 2011;27:713-30.
52. Wisloff T, Abrahamsen TG, Bergsaker MAR, et al. Cost effectiveness of adding 7-valent pneumococcal conjugate (PCV-7) vaccine to the Norwegian childhood vaccination program. Vaccine. 2006;24:5690-5699.
53. Ward A, Bozkaya D, Fleischmann J, et al. Modeling the economic and health consequences of managing chronic osteoarthritis pain with opioids in Germany: comparison of extended-release oxycodone and OROS hydromorphone. Curr Med Res Opin. 2007;23:2333-45.
54. de Cock E, Sorensen S, Levrat F, et al. Cost-effectiveness of linezolid versus vancomycin for hospitalized patients with complicated skin and soft-tissue Infections in France. Médecine et maladies infectieuse. 2009;39:330-340.
55. van Laere K, Everaert L, Annemans L, et al. The cost effectiveness of 123I-FP-CIT SPECT imaging in patients with an uncertain clinical diagnosis of parkinsonism. Eur J Nucl Med. 2008;35:1367-76.
56. Punekar YS, Sunderland T, Hawkins N, Lindsay J. Cost-Effectiveness of Scheduled Maintenance Treatment with Infliximab for Pediatric Crohn's Disease. Value in health. 2010;13:188-195.
57. Dewilde S, Verdian L, Maclaine GD. Cost-effectiveness of ziconotide in intrathecal pain management for severe chronic pain patients in the UK. Curr Med Res Opin. 2009;25:2007-19.
58. Xie X, Vondeling H. Cost-utility analysis of intensive blood glucose control with metformin versus usual care in overweight type 2 diabetes mellitus patients in Beijing, P.R. China. Value in health. 2008;11 Suppl 1**,** S23-32.
59. Simpson KN, Jones WJ, Rajagopalan R, Dietz B. Cost effectiveness of Lopinavir/Ritonavir tablets compared with Atazanavir plus Ritonavir in antiretroviral-experienced patients in the UK, France, Italy and Spain. Clin Drug Investig. 2007;27**:**807-817.
60. Bjegovic V, Terzic Z, Marinkovic J, et al. The burden of type 2 diabetes in Serbia and the cost-effectiveness of its management. Eur J Health Econ. 2007; 8**:**97-103.

Note: The above reports are the studies we used in Part 2 of our study, in which we purposively sampled HEDMs that used EKE in order to determine the methods used in eliciting expert knowledge in contemporary HEDMs.